Can successful vaccines teach us how to induce efficient protective immune responses?

Nature Medicine

Volumn 11, Issue 4S, 2005, Pages S54-

  Lambert, Paul Henri ^a   Liu, Margaret ^b   Siegrist, Claire Anne ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b TRANSGENE S A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; BCG VACCINE; GAMMA INTERFERON; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B ANTIBODY; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 12; LIVE VACCINE; MATERNAL ANTIBODY; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PALIVIZUMAB; RABIES IMMUNOGLOBULIN; TOLL LIKE RECEPTOR; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGENIC VARIATION; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIPHTHERIA; DRUG EFFICACY; EFFECTOR CELL; HAEMOPHILUS INFLUENZAE; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; INFECTION; INFLUENZA; INFLUENZA VIRUS; MEASLES; MEMORY CELL; MORTALITY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PASSIVE IMMUNIZATION; PERTUSSIS; PLACENTAL TRANSFER; PLASMODIUM FALCIPARUM; POLIOMYELITIS; PRIORITY JOURNAL; RABIES; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SMALLPOX; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TETANUS; TUBERCULOSIS; VARICELLA ZOSTER VIRUS; WART VIRUS;

AGED; ANTIBODIES; ANTIBODY AFFINITY; ANTIGENIC VARIATION; ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; INFANT; VACCINES;

ANIMALIA; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE SEROTYPE B; HERPES; HERPES ZOSTER; HUMAN HERPESVIRUS 3; HUMAN PAPILLOMAVIRUS TYPES; INFLUENZA VIRUS; MENINGOCOCCUS; MYCOBACTERIUM BOVIS BCG; NEISSERIA MENINGITIDIS; PLASMODIUM FALCIPARUM; RESPIRATORY SYNCYTIAL VIRUS; STREPTOCOCCUS PNEUMONIAE; VARIOLA VIRUS;

EID: 17644364706     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1216     Document Type: Article

References (91)

1. Janeway, C.A. Use of concentrated human serum y-globulin in the prevention and attenuation of measles. Bull. N. Y. Acad. Med. 21, 202-222 (1945).
2. Keller, M.A. & Stiehm, E.R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13, 602-614 (2000).
3. Fox, J.P. Modes of action of poliovirus vaccines and relation to resulting immunity. Rev. infect. Dis. 6 (Suppl. 2), S352-S355 (1984).
4. De Quadros, C.A. Polio. in The Vaccine Book (eds. Bloom, B.R. & Lambert, P.H.) 189-196 (Academic Press, Amsterdam, 2003).
5. Strebel, P.M., Papania, M.J. & Halsey, N.A. Measles vaccine. in Vaccines (eds. Plotkin, S.A. & Orenstein, W.A.) 389-440 (Elsevier, Philadelphia, 2004).
6. Lampe, R.M., Weir, M.R., Scott, R.M. & Weeks, J.L. Measles reimmunization in children immunized before 1 year of age. Am. J. Dis. Child. 139, 33-35 (1985).
7. Fukuda, K., Levandowski, R.A., Bridges, C.B. & Cox, N.J. Inactivated influenza vaccines. in Vaccines (eds. Plotkin, S.A. & Orenstein, W.A.) 339-370 (Elsevier, Philadelphia, 2004).
8. Belshe, R., Maassab, H.G. & Mendelman, P.M. Influenza vaccine-live. in Vaccines (eds. Plotkin, S.A. & Orenstein, W.A.) 371-388 (Elsevier, Philadelphia, 2004).
9. Davies, J.R. & Grilli, E.A. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol. infect. 102, 325-333 (1989).
10. Treanor, J.J. et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18, 899-906 (1999).
11. Belshe, R.B. et al. Correlates of immune protection induced by live, attenuated, cold- adapted, trivalent, intranasal influenza virus vaccine. J. infect. Dis. 181, 1133-1137 (2000).
12. Manz, R.A., Hauser, A.E., Hiepe, F. & Radbruch, A. Maintenance of serum antibody levels. Annu. Rev. Immunol. (in the press).
13. McHeyzer-Williams, L.J. & McHeyzer-Williams, M. Antigen-specific memory B cell development. Annu. Rev. Immunol. (in the press).
14. Gourley, T.S., Wherry, E.J., Masopust, D. & Ahmed, R. Generation and maintenance of immunological memory. Semin. Immunol. 16, 323-333 (2004).
15. Tokoyoda, K., Egawa, T., Sugiyama, T., Choi, B.I. & Nagasawa, T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. immunity 20, 707-718 (2004).
16. Ochsenbein, A.F. et al. Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proc. Natl. Acad. Sci. USA 97, 1326313268 (2000).
17. Zinkernagel, R.M. On differences between immunity and immunological memory. Curr. Opin. Immunol. 14, 523-536 (2002).
18. Bernasconi, N.L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202 (2002).
19. Pinschewer, D.D. et al. Kinetics of protective antibodies are determined by the viral surface antigen. J. Clin. invest. 114, 988-993 (2004).
20. Nicol, M. et al. Haemophilus influenzae type b conjugate vaccine diluted tenfold in diphtheria-tetanus-whole cell pertussis vaccine: A randomized trial. Pediatr. infect. Dis. J. 21, 138-141 (2002).
21. Cassidy, W.M. et al. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: Antibody responses, safety, and immunologic memory. Pediatrics 107, 626-631 (2001).
22. Ahman, H., Kayhty, H., Vuorela, A., Leroy, O. & Eskola, J. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine 17, 2726-2732 (1999).
23. Bosnak, M., Dikici, B., Bosnak, V. & Haspolat, K. Accelerated hepatitis B vaccination schedule in childhood. Pediatr. int. 44, 663-665 (2002).
24. Zinkernagel, R.M. et al. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: A geographical view of immune reactivity. Immunol. Rev. 156, 199-209 (1997).
25. Deloye, F., Doussau, F. & Poulain, B. Action mechanisms of botulinum neurotoxins and tetanus neurotoxins. C.R. Seances Soc. Biol. Fil. 191, 433-450 (1997).
26. Turton, K., Chaddock, J.A. & Acharya, K.R. Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem. Sci. 27, 552-558 (2002).
27. Matsuda, M., Kamei, M., Sugimoto, N., Ma, Y. & Hashizume, S. Characteristics of toxin-neutralization by anti-tetanus human monoclonal antibodies directed against the three functional domains [A], [B] and [C] of the tetanus toxin molecule and a reliable method for evaluating the protective effects of monoclonal antibodies. Eur. J. Epidemiol. 8, 1-8 (1992).
28. Gupta, R.K. & Siber, G.R. Comparative analysis of tetanus antitoxin titers of sera from immunized mice and guinea pigs determined by toxin neutralization test and enzyme- linked immunosorbent assay. Biologicals 22, 215-219 (1994).
29. Siegrist, C.A. et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 23, 615-622 (2004).
30. Pihlgren, M. et al. CpG-motifs enhance initial and sustained primary tetanus-specific antibody secreting cell responses in spleen and bone marrow, but are more effective in adult than in neonatal mice. Vaccine 21, 2492-2499 (2003).
31. Usinger, W.R. & Lucas, A.H. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 67, 2366-2370 (1999).
32. Golaz, A. et al. Evaluation of a single dose of diphtheria-tetanus toxoids among adults in Odessa, Ukraine, 1995: Immunogenicity and adverse reactions. J. Infect. Dis. 181 Suppl 1, S203-S207 (2000).
33. Banatvala, J., Van Damme, P. & Van Hattum, J. Boosters for hepatitis B. European Consensus Group on Hepatitis B Immunity. Lancet 356, 337-338 (2000).
34. Goldblatt, D., Vaz, A.R. & Miller, E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis. 177, 1112-1115 (1998).
35. Goldblatt, D., Miller, E., McCloskey, N. & Cartwright, K. Immunological response to conjugate vaccines in infants: Follow up study. Br. Med. J. 316, 1570-1571 (1998).
36. McVernon, J., Johnson, P.D., Pollard, A.J., Slack, M.P. & Moxon, E.R. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch. Dis. Child. 88, 379-383 (2003).
37. Kelly, D.F., Moxon, E.R. & Pollard, A.J. Haemophilus influenzae type b conjugate vaccines. Immunology 113, 163-174 (2004).
38. Trotter, C.L., Andrews, N.J., Kaczmarski, E.B., Miller, E. & Ramsay, M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364, 365-367 (2004).
39. Davidkin, I., Peltola, H., Leinikki, P. & Valle, M. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Vaccine 18, 3106-3112 (2000).
40. Thomas, S.L. & Hall, A.J. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect. Dis. 4, 26-33 (2004).
41. Kaufmann, S.H.E. & McMichael, A. Annulling a dangerous liaison: Vaccination strategies against AIDS and tuberculosis. Nat Med. 11, Suppl 1, S33-S44 (2005).
42. Salmaso, S. et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: The Italian experience. Pediatrics 108, E81 (2001).
43. Giuliano, M. et al. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J. Pediatr. 132, 983-988 (1998).
44. Gans, H.A. et al. IL-12, IFN-y, and T cell proliferation to measles in immunized infants. J. Immunol. 162, 5569-5575 (1999).
45. Alonso, P.L. et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomised controlled trial. Lancet 364, 1411-1420 (2004).
46. Ballou, W.R. et al. Update on the clinical development of candidate malaria vaccines. Am. J. Trop. Med. Hyg. 71, 239-247 (2004).
47. Hoskins, T.W., Davies, J.R., Smith, A.J., Miller, C.L. & Allchin, A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s Hospital. Lancet 1, 33-35 (1979).
48. Powers, D.C. & Belshe, R.B. Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: Effects of aging and “original antigenic sin”. J. Infect. Dis. 169, 1125-1129 (1994).
49. Smith, D.J., Forrest, S., Ackley, D.H. & Perelson, A.S. Variable efficacy of repeated annual influenza vaccination. Proc. Natl. Acad. Sci. USA 96, 14001-14006 (1999).
50. Voordouw, A.C. et al. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. J. Am. Med. Assoc. 292, 2089-2095 (2004).
51. Robbins, F.C. The history of polio vaccine development. in Vaccines (eds. A., P.S. & Orenstein, W.A.) 17-30 (Elsevier, Philadelphia, 2004).
52. Bresee, J.S., Glass, R.I., Parashar, U. & Gentsch, J.G. Rotavirus. in The Vaccine Book (eds. Bloom, B.R. & Lambert, P.H.) 225-243 (Academic Press, Amsterdam, 2003).
53. Hackell, J.G. Pneumococcus, pneumococcal disease and prevention. in The Vaccine Book (eds. Bloom, B.R. & Lambert, P.H.) 257-277 (Academic Press, Amsterdam, 2003).
54. Hausdorff, W.P., Bryant, J., Paradiso, P.R. & Siber, G.R. Which pneumococcal sero- groups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis. 30, 100-121 (2000).
55. Bosch, F.X. et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87, 796-802 (1995).
56. Kaplan, S.L. et al. Decrease of invasive pneumococcal infections in children among 8 children’s hospitals in the United States after the introduction of the 7-valent pneu- mococcal conjugate vaccine. Pediatrics 113, 443-449 (2004).
57. Siegrist, C.A. Neonatal and early life vaccinology. Vaccine 19, 3331-3346 (2001).
58. Gans, H.A. et al. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. J. Am. Med. Assoc. 280, 527-532 (1998).
59. Vazquez, M. et al. Effectiveness over time of varicella vaccine. J. Am. Med. Assoc. 291, 851-855 (2004).
60. Pihlgren, M. et al. Unresponsiveness to lymphoid-mediated signals at the neonatal follicular dendritic cell precursor level contributes to delayed germinal center induction and limitations of neonatal antibody responses to T-dependent antigens. J. Immunol. 170, 2824-2832 (2003).
61. Pihlgren, M. et al. Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. Eur. J. Immunol. 31, 939-946 (2001).
62. Goriely, S. et al. Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J. Immunol. 166, 2141-2146 (2001).
63. De Wit, D. et al. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleo- tides are impaired in human newborns. Blood 103, 1030-1032 (2004).
64. Goriely, S. et al. A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J. Exp. Med. 199, 1011-1016 (2004).
65. Ota, M.O. et al. Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults. Vaccine 22, 511-519 (2004).
66. Marchant, A. et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J. Immunol. 163, 2249-2255 (1999).
67. Ota, M.O. et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 168, 919-925 (2002).
68. Dagan, R. et al. Immunization against hepatitis A in the first year of life: Priming despite the presence of maternal antibody. Pediatr. Infect. Dis. J. 19, 1045-1052 (2000).
69. Shapiro, E.D. et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325, 1453-1460 (1991).
70. Bjorkholm, B., Hagberg, L., Sundbeck, G. & Granstrom, M. Booster effect of low doses of tetanus toxoid in elderly vaccinees. Eur. J. Clin. Microbiol. Infect. Dis. 19, 195-199 (2000).
71. Pawelec, G. et al. Is immunosenescence infectious? Trends Immunol. 25, 406-410 (2004).
72. Gomez, I., Marx, F., Gould, E.A. & Grubeck-Loebenstein, B. T cells from elderly persons respond to neoantigenic stimulation with an unimpaired IL-2 production and an enhanced differentiation into effector cells. Exp. Gerontol. 39, 597-605 (2004).
73. Powers, D.C. & Belshe, R.B. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J. Infect. Dis. 167, 584-592 (1993).
74. American Academy of Pediatrics. Tetanus. in Red Book 2003. Report of the Committee on Infectious Diseases 26th edn. (ed. Pickering, L.K.) 611-616 (American Academy of Pediatrics, Elk Grove Village, Illinois, USA, 2003).
75. Gupta, P.S., Kapoor, R., Goyal, S., Batra, V.K. & Jain, B.K. Intrathecal human tetanus immunoglobulin in early tetanus. Lancet 2, 439-440 (1980).
76. American Academy of Pediatrics. Diphtheria. in Red Book 2003. Report of the Committee on Infectious Diseases 26th edn. (ed. Pickering, L.K.) 263-266 (American Academy of Pediatrics, Elk Grove Village, Illinois, USA, 2003).
77. Morris, D. & McDonald, J.C. Failure of hyper-immune globulin to prevent whooping cough. Arch. Dis. Child. 32, 236-239 (1957).
78. Edwards, K.M. Pertussis: An important target for maternal immunization. Vaccine 21, 3483-3486 (2003).
79. Siber, G.R. et al. Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease. J. Infect. Dis. 165 Suppl 1, S129-S133 (1992).
80. Gershon, A.A. Measles virus (rubeola). in Principles and Practice of Infectious Diseases 4th edn. (eds. Mandel, G.L., Bennett, J.E. & Dolin, R.) 1519-1528 (Churchill Livingstone, New York, 1995).
81. American Academy of Pediatrics. Measles. in Red Book 2003. Report of the Committee on Infectious Diseases 26th edn. (ed. Pickering, L.K.) 419-429 (American Academy of Pediatrics, Elk Grove Village, Illinois, USA, 2003).
82. Centers for Disease Control and Prevention. Human rabies prevention-United States, 1999. Recommendations of Advisory Committee (ACIP). MMWRMorbid. Mortal. Wkly. Rep. 48, 1-21 (1999).
83. Hankins, D.G. & Rosekrans, J.A. Overview, prevention, and treatment of rabies. Mayo Clin. Proc. 79, 671-676 (2004).
84. Kempe, C.H. et al. The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull. World Health Org. 25, 41-48 (1961).
85. Galmiche, M.C., Goenaga, J., Wittek, R. & Rindisbacher, L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254, 71-80 (1999).
86. American Academy of Pediatrics. Hepatitis A. in Red Book 2003. Report of the Committee on Infectious Diseases 26th edn. (ed. Pickering, L.K.) 309-318 (American Academy of Pediatrics, Elk Grove Village, Illinois, USA, 2003).
87. Centers for Disease Control and Prevention. Postexposure prophylaxis of hepatitis B. MMWR Morbid. Mortal. Wkly. Rep. 33, 398-402 (1984).
88. Terrault, N.A. et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24, 1327-1333 (1996).
89. Storch, G.A. Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics 102, 648-651 (1998).
90. Givner, L.B. Monoclonal antibodies against respiratory syncytial virus. Pediatr. Infect. Dis. J. 18, 541-542 (1999).
91. Fisher, R.G. & Edwards, K.M. Varicella-zoster. Pediatr. Rev. 19, 62-67 (1998).